CompletedPhase 2NCT03395080
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Leap Therapeutics, Inc.
- Principal Investigator
- Cynthia Sirard, M.DLeap Therapeutics
- Intervention
- Paclitaxel(drug)
- Enrollment
- 111 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2018 – 2021
Study locations (17)
- University of Alabama, Birmingham, Alabama, United States
- HonorHealth, Scottsdale, Arizona, United States
- Florida Cancer Specialists & Research Institute, West Palm Beach, Florida, United States
- University of Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- HCA Midwest Health System Clinical Research, Kansas City, Missouri, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Ohio State University Wexner Medical Center, Hilliard, Ohio, United States
- Stephenson Cancer Center - University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- The University of Tennessee West Cancer Center, Germantown, Tennessee, United States
- Tennessee Oncology, PLLC, Nashville, Tennessee, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- University of Virginia Cancer Center, Charlottesville, Virginia, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03395080 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.